Disease details

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

6 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2005-001340-22-CZ (EUCTR)	09/04/2006	30/08/2005	BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS	BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS	Multiple sclerosis results from an auto-immune reaction characterized by inflammation within the nervous system. Myelin basic protein is a target of the autoimmune response and is generally regarded as the predominant autoantigen.BHT-3009 is a 3.5 kb bacterial plasmid expression vector containing the coding sequences for full length human myelin basic protein (hMBP).	Product Name: BHT-3009 Product Code: BHT-3009	Bayhill Therapeutics	NULL	Not Recruiting			Female: yes Male: yes	252		Finland;United Kingdom;Czech Republic
2	NCT00382629 (ClinicalTrials.gov)	February 2006	27/9/2006	BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis	BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Drug: BHT-3009 0.5 mg;Drug: BHT-3009 1.5 mg;Drug: Placebo	Bayhill Therapeutics	NULL	Completed	18 Years	55 Years	Both	252	Phase 2	NULL
3	EUCTR2005-001340-22-FI (EUCTR)	29/11/2005	22/07/2005	BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS	BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS	Multiple sclerosis results from an auto-immune reaction characterized by inflammation within the nervous system. Myelin basic protein is a target of the autoimmune response and is generally regarded as the predominant autoantigen.BHT-3009 is a 3.5 kb bacterial plasmid expression vector containing the coding sequences for full length human myelin basic protein (hMBP).	Product Name: BHT-3009 Product Code: BHT-3009	Bayhill Therapeutics	NULL	Not Recruiting			Female: yes Male: yes	252		Finland;Czech Republic;United Kingdom
4	EUCTR2005-001340-22-SK (EUCTR)	27/09/2005	29/07/2005	BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS	BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS	Multiple sclerosis results from an auto-immune reaction characterized by inflammation within the nervous system. Myelin basic protein is a target of the autoimmune response and is generally regarded as the predominant autoantigen.BHT-3009 is a 3.5 kb bacterial plasmid expression vector containing the coding sequences for full length human myelin basic protein (hMBP).	Product Name: BHT-3009 Product Code: BHT-3009	Bayhill Therapeutics	NULL	Not Recruiting			Female: yes Male: yes	252	Phase 2	Czech Republic;Slovakia;Finland;United Kingdom
5	EUCTR2005-001340-22-GB (EUCTR)	12/08/2005	18/07/2005	BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS	BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS	Multiple sclerosis results from an auto-immune reaction characterized by inflammation within the nervous system. Myelin basic protein is a target of the autoimmune response and is generally regarded as the predominant autoantigen.BHT-3009 is a 3.5 kb bacterial plasmid expression vector containing the coding sequences for full length human myelin basic protein (hMBP).	Product Name: BHT-3009 Product Code: BHT-3009	Bayhill Therapeutics	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	252		Finland;Czech Republic;United Kingdom
6	NCT00103974 (ClinicalTrials.gov)	July 2004	17/2/2005	Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis	A Phase I Trial of Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis	Multiple Sclerosis	Biological: BHT-3009-01	Bayhill Therapeutics	NULL	Completed	18 Years	65 Years	Both	30	Phase 1	United States;Canada

先頭へ